Dr. Lingxiang Chen 陈凌翔
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Molecular targeted therapy and immunotherapy for lung cancer, gastrointestinal tumors, and malignant melanoma.
Dr. Chen is a Chief Physician in the Department of Medical Oncology at Jiangsu Cancer Hospital. Dr. Chen serves on several provincial committees, including the Jiangsu Medical Association and Jiangsu Anti-Cancer Association. Clinical expertise includes diagnosis and chemotherapy for malignant tumors, with a focus on molecular targeted therapy and immunotherapy for advanced lung and gastrointestinal cancers.
Professional roles
- Deputy Leader, Precision Molecular Therapy Group, Jiangsu Medical Doctor Association
- Member, Oncology Chemotherapy and Biotherapy Committee, Jiangsu Medical Association
- Secretary, Chemotherapy Professional Committee, Jiangsu Anti-Cancer Association
- Youth Member, Neuroendocrine Tumor Branch, China International Exchange and Promotion Association for Medicine and Healthcare
Name order: in Chinese the family name comes first (Chen Lingxiang). Papers usually list the name as Lingxiang Chen or Chen L.
Selected publications
12 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Recent Pat Anticancer Drug Discov, 2025 (senior author): A Single-arm, Open-label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer. PubMed 39779562
- J Gastrointest Oncol, 2021 (senior author): Correlation between L3 skeletal muscle index and prognosis of patients with stage IV gastric cancer. PubMed 34790375
- J Thorac Dis, 2020 (senior author): Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer. PubMed 33209434
- Ann Transl Med, 2020 (senior author): High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy. PubMed 32617305
- Cell Mol Biol (Noisy-le-grand), 2020 (senior author): Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery. PubMed 32415940
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion